Tue, May 13, 12:16 PM (42 days ago)
**Atossa Therapeutics, Inc. (ATOS) Q1 2025 Financial Summary** **Financial Health and Performance:** - **Revenue:** No revenue generated. - **Operating Expenses:** $7.4 million, up $0.4 million from Q1 2024. - **Net Loss:** $6.7 million, an increase from $5.9 million in Q1 2024. - **Cash Flow:** Net cash used in operating activities was $6.0 million. - **Cash Position:** $65.1 million in cash and cash equivalents as of March 31, 2025. **Key Metrics:** - **Operating Loss:** $7.4 million, up from $7.0 million in Q1 2024. - **Interest Income:** $0.7 million, down from $1.1 million in Q1 2024. - **Net Loss Per Share:** $0.05, unchanged from Q1 2024. **Trends and Uncertainties:** - **Operating Expenses:** Increased due to higher R&D and G&A costs. - **Cash Flow:** Negative cash flow from operations, indicating continued reliance on cash reserves. - **Future Operations:** Plans to continue funding through equity offerings, debt financings, or collaborations. **Quarterly Performance Discussion:** - **R&D Expenses:** Increased by $0.4 million, driven by higher compensation and regulatory consulting costs. - **G&A Expenses:** Slight increase due to higher compensation and insurance costs. - **Interest Income:** Decreased due to lower money market account balances. **Future Outlook:** - **Funding Requirements:** Continued need for substantial additional capital. - **Market Risks:** Volatility due to macroeconomic conditions, regulatory changes, and competitive pressures. - **Operational Impact:** Potential delays in clinical trials and regulatory approvals. **Summary:** ATOS continues to face significant financial challenges, with increasing operating losses and negative cash flow. The company relies on its cash reserves and plans to raise additional capital to sustain operations. Market risks and operational uncertainties pose further challenges to its future performance.